Biology Reference
In-Depth Information
20. Boussif O et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in
culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92(16):7297-7301
21. Sonawane ND, Szoka FC, Verkman AS (2003) Chloride accumulation and swelling in endo-
somes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 278(45):
44826-44831
22. Medina-Kauwe LK, Xie J, Hamm-Alvarez S (2005) Intracellular trafficking of nonviral vec-
tors. Gene Ther 12(24):1734-1751
23. Wolff JA, Rozema DB (2007) Breaking the bonds: non-viral vectors become chemically
dynamic. Mol Ther 16(1):8-15
24. Wattiaux R et al (2000) Endosomes, lysosomes: their implication in gene transfer. Adv Drug
Deliv Rev 41(2):201-208
25. Miller AD (1998) Cationic liposomes for gene therapy. Angew Chem Int Ed 37(13-14):
1768-1785
26. Maurer N et al (1999) Lipid-based systems for the intracellular delivery of genetic drugs. Mol
Membr Biol 16(1):129-140
27. Shmueli RB, Anderson DG, Green JJ (2010) Electrostatic surface modifications to improve
gene delivery. Expert Opin Drug Deliv 7(4):535-550
28. Kedmi R, Ben-Arie N, Peer D (2010) The systemic toxicity of positively charged lipid nano-
particles and the role of toll-like receptor 4 in immune activation. Biomaterials 31(26):
6867-6875
29. Wheeler JJ et al (1999) Stabilized plasmid-lipid particles: construction and characterization.
Gene Ther 6(2):271-281
30. Wisse E et al (2008) The size of endothelial fenestrae in human liver sinusoids: implications
for hepatocyte-directed gene transfer. Gene Ther 15(17):1193-1199
31. Akinc A et al (2009) Development of lipidoid-siRNA formulations for systemic delivery to the
liver. Mol Ther 17(5):872-879
32. Adlakha-Hutcheon G et al (1999) Controlled destabilization of a liposomal drug delivery sys-
tem enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-779
33. Webb MS et al (1998) Comparison of different hydrophobic anchors conjugated to poly(ethylene
glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta
1372(2):272-282
34. Svensson RU et al (2008) Assessing siRNA pharmacodynamics in a luciferase-expressing
mouse. Mol Ther 16(12):1995-2001
35. Sioud M (2008) Does the understanding of immune activation by RNA predict the design of
safe siRNAs? Front Biosci 13:4379-4392
36. Eberle F et al (2008) Modifications in small interfering RNA that separate immunostimulation
from RNA interference. J Immunol 180(5):3229-3237
37. Zhang HY et al (2006) RNA interference with chemically modified siRNA. Curr Top Med
Chem 6(9):893-900
38. Morrissey DV et al (2005) Potent and persistent in vivo anti-HBV activity of chemically
modified siRNAs. Nat Biotechnol 23(8):1002-1007
39. Judge AD et al (2006) Design of noninflammatory synthetic siRNA mediating potent gene
silencing in vivo. Mol Ther 13(3):494-505
40. Schlee M, Hornung V, Hartmann G (2006) siRNA and isRNA: two edges of one sword. Mol
Ther 14(4):463-470
41. Nguyen DN et al (2009) Drug delivery-mediated control of RNA immunostimulation. Mol
Ther 17(9):1555-1562
42. Frank-Kamenetsky M et al (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma
cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA
105(33):11915-11920
43. Epiphanio S et al (2008) Heme oxygenase-1 is an anti-inflammatory host factor that promotes
murine plasmodium liver infection. Cell Host Microbe 3(5):331-338
44. Huang Y-H et al (2009) Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth
and metastasis. Proc Natl Acad Sci USA 106(9):3426-3430
Search WWH ::
Custom Search